Anthrax News and Research

RSS
Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in wild and domestic lower vertebrates (cattle, sheep, goats, camels, antelopes, and other herbivores), but it can also occur in humans when they are exposed to infected animals or tissue from infected animals.

Anthrax is most common in agricultural regions where it occurs in animals. These include South and Central America, Southern and Eastern Europe, Asia, Africa, the Caribbean, and the Middle East. When anthrax affects humans, it is usually due to an occupational exposure to infected animals or their products. Workers who are exposed to dead animals and animal products from other countries where anthrax is more common may become infected with B. anthracis (industrial anthrax). Anthrax outbreaks occur in the United States on an annual basis in livestock and wild game animals such as deer.

Anthrax infection can occur in three forms: cutaneous (skin), inhalation, and gastrointestinal. B. anthracis spores can live in the soil for many years, and humans can become infected with anthrax by handling products from infected animals or by inhaling anthrax spores from contaminated animal products. Anthrax can also be spread by eating undercooked meat from infected animals. It is rare to find infected animals in the United States.
PaxVax reports interim data from Phase 3 cholera challenge study of PXVX0200

PaxVax reports interim data from Phase 3 cholera challenge study of PXVX0200

SLU nursing faculty, students receive special training to operate Closed Point of Dispensing

SLU nursing faculty, students receive special training to operate Closed Point of Dispensing

Bioethics Commission releases ethical recommendations to manage incidental and secondary findings

Bioethics Commission releases ethical recommendations to manage incidental and secondary findings

Emergent BioSolutions enters into definitive agreement to acquire Cangene

Emergent BioSolutions enters into definitive agreement to acquire Cangene

Soligenix initiates SGX942 Phase 2 study for treatment of oral mucositis

Soligenix initiates SGX942 Phase 2 study for treatment of oral mucositis

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Inhibitor compounds could form basis of new treatments for such diseases as MRSA, anthrax

Inhibitor compounds could form basis of new treatments for such diseases as MRSA, anthrax

MD Anderson-developed aerosol triggers innate immunity to squelch infections

MD Anderson-developed aerosol triggers innate immunity to squelch infections

Group Health helps protect public from infectious diseases through nationwide network

Group Health helps protect public from infectious diseases through nationwide network

Soligenix awarded $6.4M contract to advance preclinical development of OrbeShield for GI ARS

Soligenix awarded $6.4M contract to advance preclinical development of OrbeShield for GI ARS

FDA grants orphan drug designation to Soligenix’s SGX94 for treatment of Acute Radiation Syndrome

FDA grants orphan drug designation to Soligenix’s SGX94 for treatment of Acute Radiation Syndrome

Pharmathene presents new data from SparVax anthrax vaccine program at 2013 Bacillus conference

Pharmathene presents new data from SparVax anthrax vaccine program at 2013 Bacillus conference

PaxVax commences phase 3 clinical trial for single-dose oral cholera vaccine candidate

PaxVax commences phase 3 clinical trial for single-dose oral cholera vaccine candidate

Chemical attacks in Syria can pose threat to US, says Homeland Security medical officer

Chemical attacks in Syria can pose threat to US, says Homeland Security medical officer

Research findings may help scientists develop anthrax treatments for humans

Research findings may help scientists develop anthrax treatments for humans

NIST and USAMRIID scientists advance crucial step in anthrax infection process

NIST and USAMRIID scientists advance crucial step in anthrax infection process

Mathematical model to help answer critical questions to large-scale anthrax exposure

Mathematical model to help answer critical questions to large-scale anthrax exposure

TGen receives $20,000 grant from ACF for STEM education

TGen receives $20,000 grant from ACF for STEM education

Emergent BioSolutions acquires Bracco Diagnostics' Healthcare Protective Products Division

Emergent BioSolutions acquires Bracco Diagnostics' Healthcare Protective Products Division